Finanzas de Palisade Bio Inc (PALI)PALIPalisade Bio Inc

Evaluating the bottom line, Palisade Bio Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2339.60%, while the net margin is -2114.80%. These profitability ratios, combined with a Return on Equity (ROE) of -51.37%, provide a clear picture of how effectively PALI converts its operational activities into shareholder value.

In the context of the broader market, PALI competes directly with industry leaders such as SLGL and SIGA. With a market capitalization of $249.21M, it holds a significant position in the sector. When comparing efficiency, PALI's gross margin of 100.00% stands against SLGL's 100.00% and SIGA's 57.17%. Such benchmarking helps identify whether Palisade Bio Inc is trading at a premium or discount relative to its financial performance.

Palisade Bio has not generated significant revenue, reporting $0.00 for multiple quarters, and a widening net loss of $10.6 million in Q2 2026. The gross margin for Q2 2026 was 100%, but this is based on minimal revenue.